Intangible Assets and Goodwill - Narrative (Details) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Jul. 02, 2024	Sep. 27, 2023	Sep. 26, 2023
Goodwill [Line Items]
Amortization and impairment of acquired intangible assets		$ 515,000,000.0	$ 446,700,000	$ 240,600,000
Amortization of intangible assets		507,100,000	386,500,000	240,600,000
Impairment of intangible assets	$ 20,200,000	7,900,000	$ 40,000,000	$ 0
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]	Amortization and impairment of acquired intangible assets		Amortization and impairment of acquired intangible assets
Accumulated impairment losses related to goodwill		$ 0	$ 0
Acquired and in-licensed rights and patents
Goodwill [Line Items]
Weighted-average remaining useful life		12 years
Minimum | Completed Technology
Goodwill [Line Items]
Estimated life (in years)		1 year
Maximum | Completed Technology
Goodwill [Line Items]
Estimated life (in years)		30 years
In-process research and development (omaveloxolone)
Goodwill [Line Items]
Intangible assets (excluding goodwill)		$ 1,635,000,000	1,642,900,000
Reata Pharmaceuticals, Inc | In-process research and development (omaveloxolone)
Goodwill [Line Items]
Intangible assets:		2,300,000,000				$ 2,300,000,000
Reata Pharmaceuticals, Inc | Priority review voucher
Goodwill [Line Items]
Intangible assets:		$ 100,000,000.0					$ 100,000,000
Reata Pharmaceuticals, Inc | In-process research and development (omaveloxolone)
Goodwill [Line Items]
Intangible assets (excluding goodwill)			$ 0
Human Immunology Biosciences
Goodwill [Line Items]
Intangible assets:					$ 1,600,000,000